Extrapyramidal side-effects and antipsychotics: Are second-generation agents still indicated?

摘要

Peluso et al report on the differential effect of first-generation antipsychotics (FGAs) v. second-generation antipsychotics (SGAs) in ameliorating or exacerbating extrapyramidal side-effects (EPS) in a secondary analysis of the CUtLASS-1 trial data.1 They report their findings as 'essentially null' and mention that there is weak evidence for clinically significant differences in emergent or relieved EPS between FGAs and SGAs. These findings, although based on a secondary analysis, pose interesting and important challenges for the focus of future research, but also raise some questions about the interpretation of negative study findings.